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Enzymes of the M4 family of zinc-metalloproteinases are virulence factors secreted from gram-
positive or gram-negative bacteria, and putative drug targets in the treatment of bacterial 
infections. In order to have a therapeutic value such inhibitors should not interfere with 
endogenous zinc-metalloproteinases.   In the present study we have synthesised a series of 
hydroxamate derivatives and validated the compounds as inhibitors of the M4 enzymes 
thermolysin and pseudolysin, and the endogenous metalloproteinases ADAM-17, MMP-2 and 
MMP-9 using experimental binding studies and molecular modelling. In general, the 
compounds are stronger inhibitors of the MMPs than of the M4 enzymes, however, an 
interesting exception is LM2. The compounds bound stronger to pseudolysin than to 
thermolysin, and the molecular modelling studies showed that occupation of the S2
’ subpocket 
by an aromatic group is favourable for strong interactions with pseudolysin.  
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     The discovery and approval of new antibacterial drugs has stagnated, and it is an urgent need 
to develop new effective strategies against bacterial infections with a low risk for resistance 
development. Selective inhibitors weakening the pathogen without directly targeting its 
viability is a promising strategy since the pathogen will have reduced capacity to suppress or 
avoid the host immune system [1]. Such inhibitors can be used as adjuvants to reduce the 
concentration of antibiotics, and thereby reduce the risk of resistance development. 
Thermolysin and pseudolysin belong to the M4 family of metalloproteinases 
(http://merops.sanger.ac.uk). Most of the M4 family members are virulence factors secreted 
from gram-positive or gram-negative bacteria [2, 3]. These enzymes degrade extracellular 
proteins and peptides that the bacteria uses for nutrition prior to sporulation. The family 
includes enzymes from pathogens such as Legionella, Listeeria, Clostridium, Staphylococcus, 
Pseudomonas and Vibrio, and are important contributors in various bacterial infections [4]. 
Inhibitors of pseudolysin and thermolysin may weaken the pathogen and be a putative strategy 
in the fight against bacterial infections [5-9].  In order to have therapeutic potentials, bacterial 
M4 enzyme inhibitors should not interfere with the substrate degradation of endogenous zinc 
metalloproteinases of the infected host, like the matrix metalloproteinases (MMPs) and the 
adamalysins (ADAMs). 
     Thermolysin from Bacillus B. thermoproteolyticus was the first enzyme of the M4 family to 
be sequenced and to have the three-dimensional (3D) structure determined, and the family was 
also named the thermolysin family of metalloproteinases. The X-ray crystal structures of the 
M4 family members show that the enzymes contain a catalytic zinc ion coordinated by three 
amino acids and a water molecule [10]. However, they have structural similarities with 
endogenous zinc metalloproteinases in the region of the catalytic site [4, 11]. Obtaining 
appropriate specificity is therefore problematic in the development of compounds targeting M4 
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zinc metalloproteinases. Both peptidic and non-peptidic molecules have been identified as 
thermolysin [12-14] and pseudolysin [15, 16] inhibitors, and so far all published compounds 
target the catalytic zinc. However, an exhaustive study able to lead to the discovery of 
nanomolar and selective thermolysin or pseudolysin non-peptidic inhibitors is still missing. The 
crystal structures complexes with small molecules show that upon binding, the zinc 
coordinating water molecule is replaced by one or two oxygen atoms from the inhibitor forming 
a monodentate or bidentate arrangements with the catalytic zinc ion [17-19]. The X-ray 
complexes also show that the overall geometry of the binding pocket can be divided into three 
subpockets, the S1
’-, S2
’-, and S1-subpockets [4, 20]. The S1
’-subpocket is the main binding 
region for substrate recognition, and accommodates specifically hydrophobic amino acids of 
the substrate, both for thermolysin and pseudolysin. The S2
’ – subpocket is also quite 
hydrophobic, while the S1 – subpocket is larger and more hydrophilic than the other two 
subpockets.  
     In an effort to develop selective thermolysin and pseudolysin inhibitors able to spare the 
human MMPs and ADAMs, we have, in the present study used compounds belonging to our 
in-house library of MMP inhibitors. Some new or already published compounds, with a low 
affinity against MMPs (in the micromolar range) were chosen and screened against thermolysin 
and pseudolysin, while some nanomolar MMP-2 inhibitors were selected as reference 
compounds. The series of compounds used in the present study are hydroxamates belonging to 
several chemical classes, all derived from a common general structure: secondary and tertiary 
arylsulfonamides, arylamides, biarylsulfones, N-benzyloxy aminoacid hydroxamates (Fig. 1). 
Such a chemical diversity could be useful to identify the structural characteristics necessary to 
have a strong binding to thermolysin and pseudolysin catalytic sites. Hydroxamates were 
chosen because they are known to have a strong zinc-chelating effect. The compounds were 
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     The compounds ARP101, EN178, LM2 and FC19 were synthesised as previously reported 
[21-24]. Compound EN204 was prepared as described in Scheme 1. Sulfonamide 1 [25] was 
alkylated by treatment with 1-iodo-2-methylpropane in DMF using potassium carbonate as base. 
Subsequently, N-isobutyl derivative 2 was submitted to acid hydrolysis to give carboxylate 3 
which was finally converted into the corresponding hydroxamate EN204 by condensation with 
O-(tert-butyldimethylsilyl)hydroxylamine and acid cleavage by trifluoroacetic acid (TFA). 
 



























a Reagents and conditions: (a) K2CO3, isobutyl iodide, DMF; (b) TFA, CH2Cl2, 0 °C; (c) 
TBDMSiONH2, EDC, CH2Cl2; (d) TFA, CH2Cl2, 0 °C. 
 
Compound FO9 was synthesised as described in Scheme 2. Biphenyl-4-sulfonyl chloride was 
added to 3-aminopropanoic acid in water and dioxane using triethylamine (TEA) as base. 
Carboxylate 4 was then condensed with O-(tert-butyldimethylsilyl)hydroxylamine in the 
presence of 1-[3-(dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride (EDC) to give 
silyl intermediate 5 which afforded hydroxamate FO9 after acid cleavage with TFA. 
 






























a Reagents and conditions: (a) TEA, H2O, dioxane; (b) TBDMSiONH2, EDC, CH2Cl2; (d) TFA, 
CH2Cl2, 0 °C. 
 
Compound FC31 was synthesised as reported in Scheme 3. tert-Butyl ester 7 was prepared by 
esterification of carboxylic acid 6 [24] with N,N-dimethylformamide di-tert-butyl acetal in 
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toluene. The phenolic group of compound 7 was alkylated by treatment with 2-(3-
bromopropyl)isoindoline-1,3-dione in acetone using potassium carbonate as base to give 8. 
Ester 8 was oxidized to the corresponding sulfone 9 using Oxone in methanol/THF/H2O, and 
subsequently hydrolyzed to the corresponding carboxylic acid 10 by treatment with TFA. 
Carboxylate 10 was finally converted into the corresponding hydroxamate FC31 by 
condensation with O-(tert-butyldimethylsilyl)hydroxylamine and acid cleavage by TFA. 
 
Scheme 3. Synthesis of compound FC31  
 
 
a Reagents and conditions: (a) (CH3)2NCH[OC(CH3)3]2, toluene, 95ºC; (b) K2CO3, 2-(3-
bromopropyl)isoindoline-1,3-dione, acetone, reflux; (c) Oxone, MeOH, THF, H2O; (d) TFA, 




Compound ML25 was synthesised as reported in Scheme 4. Carboxylic acid 12 was prepared 
by acid hydrolysis of the previously described tert-butyl ester 11 [26]. The corresponding 
hydroxamic acid ML25 was obtained by condensation of 12 with O-(tert-
butyldimethylsilyl)hydroxylamine followed by acid cleavage with TFA. 
 





























a Reagents and conditions: (a) TFA, CH2Cl2, 0 °C; (b) TBDMSiONH2, EDC, CH2Cl2; (c) TFA, 
CH2Cl2, 0 °C. 
 
Compound EN181 was prepared as reported in Scheme 5. Commercially available 4-
phenoxybenzoic acid was reacted with O-isopropylhydroxylamine hydrochloride in the 
presence of N-methylmorpholine (NMM) and EDC in CH2Cl2 to give the isopropoxyamide 13. 
A Mitsunobu reaction of 13 with the alcohol 14 [27] in the presence of diisopropyl 
azodicarboxylate (DIAD) and triphenylphosphine gave the tert-butyl ester 15 which was 
converted to its corresponding carboxylate 16 by acid hydrolysis with TFA. Hydroxamic acid 
EN181 was finally obtained by condensation of 16 with O-(tert-







Scheme 5. Synthesis of compound EN181 
 
a Reagents and conditions: (a) O-isopropyl hydroxylamine HCl, NMM, EDC, CH2Cl2; (b) PPh3, 
DIAD, THF; (c) TFA, CH2Cl2, 0 °C; (d) TBDMSiONH2, EDC, CH2Cl2; (e) TFA, CH2Cl2, 0 °C; 
 
Compound CC30 was prepared as reported in Scheme 6. Commercially available 4-
methoxybenzene-1-sulfonyl chloride was reacted with O-(1-adamantyl)oxyamine 17 in THF, 
yielding sulfonamide 18, which was alkylated with tert-butyl bromoacetate to give ester 19. 
Acid hydrolysis of ester 19 afforded carboxylate 20, which was finally converted to its 
corresponding hydroxamate by condensation with O-(tert-butyldimethylsilyl)hydroxylamine 
and acid cleavage by TFA. 
 




a Reagents and conditions: (a) 4-methoxybenzene-1-sulfonyl chloride, NMM, THF; (b) 
BrCH2COOt-Bu, Cs2CO3, Bu4NHSO4, DMF; (c) TFA, CH2Cl2, 0°C; (d) TBDMSiONH2, EDC, 
CH2Cl2; (e) TFA, CH2Cl2, 0°C. 
 
2.2. Determination of Km for thermolysin and pseudolysin 
     During the conditions used, Km values for the fluorogenic Abz-Ala-Gly-Leu-Ala-p-
nitrobenzylamide (AGLA) substrate with thermolysin and pseudolysin were 68 ± 10 and 128 ± 
23 µM, respectively, while the corresponding values for the fluorogenic substrate Mca-Arg-
Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys-(Dnp)-OH -(Bradykinin-like substrate; BLS) were 15 ± 3 
and 10 ± 3 µM. With the AGLA substrate this resulted in [S]/Km values of 0.22 for thermolysin 
and 0.08 for pseudolysin, while the corresponding values for BLS were 0.11 and 0.17. The 
relation between Ki and IC50 for a substrate competitive inhibitor is Ki = IC50 / (1+[S]/Km). Thus 
the obtained IC50 values for the two enzymes with the two different substrates will reflect the 
dissociation constant Ki. 
 
2.3. Enzyme inhibition studies 
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     IC50 values of the compounds were measured in vitro both for thermolysin and pseudolysin 
using the fluorogenic substrates AGLA and BLS. The new hydroxamates EN204, FO9, FC31, 
EN181, ML25 and CC30 were also tested in vitro for their ability to inhibit human recombinant 
MMP-2 and MMP-9 by a fluorometric assay, with the fluorogenic peptide Mca-Lys-Pro-Leu-
Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 (FS-6) [28] as the substrate. MMP-2, MMP-9, and ADAM-
17 were chosen among the 23 human MMPs and 21 human ADAMs as prototype enzymes to 
test the selectivity of the new compounds. The compounds ARP101 [21, 26], EN178 [22], FC19 
[24] and LM2 [23] have previously been tested for inhibition of different MMPs including 
MMP-2 and MMP-9. The IC50 values are shown in Table 1.  
     In general, the compounds exhibit a stronger inhibition of the MMPs than of the bacterial 
M4 enzymes and ADAM-17 (Table 1).  In particular, ARP101, EN178, EN204 which inhibit 
MMP-2 and MMP-9 in the nM range. The benzyloxy aminoacid hydroxamate LM2 is the only 
compound that shows a stronger inhibition of pseudolysin and thermolysin than of MMP-2, 
MMP-9 and ADAM-17 (Table 1). In fact, the inhibitory activities (IC50 values) of LM2 toward 
the M4 enzymes are in the range of 1.1- 9.5 µM while the IC50 values toward MMP-2, MMP-9 
and ADAM-17 are 34, 81 and 100 µM, respectively.   
     In general, the IC50 values also indicated that the compounds bound stronger to pseudolysin 
than to thermolysin (Table 1). Several compounds such as LM2, ML25, EN181, FC19 and 
FC31 have a good binding affinity to pseudolysin, with IC50 values in the lower μM region. The 
best binders for both pseudolysin and thermolysin are LM2 and ML25 (Table 1). For 
pseudolysin, LM2 has an IC50 value of 1 to 2 μM (depending on the substrate used for the assay). 
For thermolysin, LM2 has an IC50 value of 9.5 μM. ML25 also binds quite strongly both to 
thermolysin and pseudolysin, with IC50 values in the range of 3-33 µM. 
 
2.4 Molecular modelling 
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     Molecular modelling studies were performed to study the binding modes of the compounds 
for the bacterial M4 enzymes, MMP-2 and MMP-9 and if possibly obtain structural insight into 
selective pseudolysin and thermolysin inhibition based on the in vitro enzymatic assays. All 
compounds were docked into the four enzyme structures. However, in particular three ligands 
are described in detail: LM2 (more active for M4 enzymes than for MMPs), FO9 (similar 
activity both for pseudolysin and MMP-9), and ARP101 (more active for MMPs than for M4 
enzymes). The Pseudolysin-inhibitor complexes after docking were also structurally refined by 
molecular dynamics (MD) simulations. 
     Docking into pseudolysin, MMP-2 and MMP-9 were performed with the ICM program [29]. 
Initial docking into thermolysin was performed with the Glide program of the Schrødinger 
program package [30]. However, the Glide docking could not give any clear prediction about 
the binding mode of the inhibitors in thermolysin and the inhibitors were therefore re-docked 
in thermolysin with the ICM software. Docked complexes were evaluated based on scoring and 
similarities with complexes present in the PDB-database.  
     The complexes of ARP101, FO9 and LM2 with pseudolysin and thermolysin after docking 
are shown in Fig. 2. Docking of LM2 into pseudolysin (Fig. 2) indicated that the hydroxamate 
part formed bidentate interaction with the zinc atom, while the ring system occupied the S2
’-
subpocket and the aliphatic butane chain pointed in the direction of the S1’-subpocket (Fig. 2). 
The oxygen atoms of the hydroxamate CO and OH groups interact with the zinc, while the 
hydrogen atom of the OH-groups interacts with the side chain of Glu141, and the hydroxamate 
NH forms a hydrogen bond with the backbone of Tyr114, and also interacts with His140. After 
docking, ML25 and FO9 had quite similar orientation as LM2 with the ring system occupying 
the S2
’-subpocket (Fig. 2), however, for FO9 binding poses with the ring system within the S1-
subpocket were also observed. Docking of ARP101, EN178, EN204 and FC19 indicated that 
the aromatic ring system of these compounds occupy the S1-subpocket of pseudolysin. The 
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hydroxamate NH-group of ARP101 formed a hydrogen bond with the backbone of Ala113, 
while the hydroxamate OH-group formed a hydrogen bond with Glu141   (Fig.2).   
      In thermolysin clear prediction of their binding poses was not obtained neither with Glide 
nor ICM. Both Glide and ICM docking showed docking poses for the strongest thermolysin 
binders LM2 and ML25 with their ring systems occupying both the S2
’- and the S1-subpocket, 
and based on the docking we could not rank one of the predicted orientations in front of the 
other. In both orientations LM2 and ML25 formed a bidentate interaction with the zinc. Fig. 2 
shows LM2 in a pose with the ring system in the S1-subpocket of thermolysin interacting with 
Phe114 (displayed in Fig. 2) and Asp116.  In that orientation the hydroxamate CO-groups form 
hydrogen bonds with the side chain of Arg203, while the NH-group interacts with Glu143 (Fig. 
2).  
     Several X-ray complexes of thermolysin with small molecules are available in the PDB-
database, while quite few are available for pseudolysin.  Evaluating the docking poses based on 
known X-ray complexes is therefore easier for thermolysin than for pseudolysin. The structural 
stability of the pseudolysin-inhibitor complexes was therefore tested by 24 ns of molecular 
dynamics (MD) simulations. The MD simulations indicated that pseudolysin – inhibitor 
complexes were stable during 24 ns of MD simulations, and the main interactions were similar 
before and after 24 ns of MD. Amino acids within 4 Å of the inhibitors after MD are shown in 
Table 2.  
             Docking of the compounds in MMPs indicated that the compounds interact quite 
similarly in both MMP-2 and MMP-9, with the ring system in the S1’-subpocket and with a 
bidentate interaction between the hydroxamate groups of the compound and the zinc. The 
complexes of MMP-9 with ARP101, FO9 and LM2 are shown in Fig. 3.   In MMP-9 the ring 
system of the high affinity binder ARP101 (Table 1) occupy the S1’-subpocket in between 
Leu397, Val398, His401, Leu418, and Tyr423. The SO2 group interacts with the backbone of 
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Leu187 and Ala189, the hydroxamate NH-group forms a hydrogen bond with the backbone of 
Ala189, the hydroxamate CO-group coordinates the zinc, while the OH-group coordinates the 
zinc and forms a hydrogen bond with Glu402. One of isopropyl groups of ARP101 interacts in 
the S2’-subpocket (Fig. 3). LM2 which is a much weaker MMP-2 and MMP-9 binder than 
ARP101 coordinates the zinc in the same way as ARP101, however, in contrast to ARP101 the 
hydroxamate OH-group did not form a hydrogen bond with the enzyme, and the structure did 
not penetrate deeply into the S1’- and S2’- subpocket as did ARP101.     
 
3. Discussion 
      A series of hydroxamate derivatives (Fig. 1) were synthesised and tested for their binding 
affinity to pseudolysin, thermolysin, MMP-2, MMP-9 and ADAM-17 by in vitro binding 
studies (Table 1).  Molecular modelling studies were also performed with the compounds 
interacting with thermolysin, pseudolysin, MMP-2 and MMP-9. Our studies showed that most 
of the compounds bound much stronger to MMP-2 and MMP-9 than to the bacterial M4 
enzymes and ADAM-17 (Table 1).  The only exception was LM2 that bound stronger to 
pseudolysin and thermolysin than to the human zinc metalloproteinases. 
     The average complexes after docking and MD of pseudolysin with ML25 indicated that the 
hydroxamate part formed bidentate interactions with the zinc atom, while the 2-
bromothiophene group occupied the S2
’-subpocket. LM2 had a similar orientation in 
pseudolysin with the ring system occupying the S2
’-subpocket (Fig. 2). This orientation gave 
strong interactions with amino acids in the S2
’-subpocket.  Energy decomposition of the ML25-
psedolysin interactions using the Analyze module of the AMBER package [31] showed that 
ML25 had interaction energies of – 6.4 kcal/mol with Ala 113, while the interactions with 
Leu197 and Arg198 in the S2’-subpocket were  -3.8 kcal/mol and -3.5 kcal/mol, respectively. 
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Strong interaction with amino acids in the S2
’-subpocket seems to be the main reason for that 
ML25 and LM2 are moderately strong pseudolysin binders.  
     The X-ray crystal structure of pseudolysin and thermolysin in complex with inhibitors were 
used as guides for evaluating the docking poses of the various inhibitors. Fewer experimentally 
complexes are available for pseudolysin than for thermolysin, but MD simulations for 24 ns 
showed that the obtained pseudolysin-ligand complexes were structurally stable. The 
interaction of LM2 with pseudolysin is also similar to that seen in X-ray structure complex 
(PDB id: 1u4g and 3dbk). The superimposition of the best poses from the docking experiments 
with LM2 almost replicated the pose of the inhibitor (N-(1-carboxy-3-phenylpropyl) 
phenylalanyl-alpha-asparagine) in the X-ray crystal structure with pseudolysin. Amino acids 
within 4 Å of LM2 after MD are shown in Table 2.  The two X-ray derived structures of 
pseudolysin in complex with small molecule inhibitors (1u4g and 3dbk) show that the inhibitors 
interact with Asn112, Ala113, Glu141, Arg198 and are deeply placed in the pocket consisting 
of Leu132 (S1’), Val137 (S1’), Ile186 (S2’), Leu197 (S2’),  and F129 (S2’). The docking and 
MD simulations therefore indicate that the strongest pseudolysin binder in the present study 
interacts with pseudolysin within a binding mode similar to that seen in the known X-ray crystal 
structure complexes 1u4g and 3dbk (Table 2). 
     All the ligands with butyl-side chains (ARP101, EN178 and EN204) had weak binding 
affinities for pseudolysin and thermolysin, and EN178 had the weakest pseudolysin binding of 
all studied compounds (Table 1). The docking poses of EN178, ARP101 and EN204 showed a 
lack of the important interactions within S2’-subpocket as observed for LM2, and in the X-ray 
complexes of inhibitors with pseudolysin. The complex of ARP101 with pseudolysin is shown 
in Fig. 2. In contrast to the strongest pseudolysin binder LM2, the aromatic ring systems of 
ARP101, EN178, EN204, FO9 (for most of the poses) and FC19 all occupied the S1-subpocket 
of pseudolysin after docking and MD. The hydroxamate group formed bidentate interactions 
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with the Zinc atom. The average structures after MD indicated that FC31 interacted with 
pseudolysin in a bent conformation with the phthalimide ring system in the S1-subpocket, and 
the other ring system partly in the S2
’-subpocket and partly outside the three subpockets of 
pseudolysin. FC31 also bound quite strongly to pseudolysin (Table 1).  After MD with EN181, 
the diphenyl ether group interacted in the S1-subpocket, while the phthalimide group interacted 
in the S2
’-subpocket but also had interactions outside the subpockets of pseudolysin. 
      X-ray structure complexes with thermolysin show that the S1-subpocket can accommodate 
hydrophobic ligand parts, while S1’ and S2’-subpockets can host quite similar groups and that 
hydrophobic residues of peptides are favoured. However, the S2’-subpocket is more easily 
accessible for water molecules than the S1-subpocket [32]. Docking LM2 and ML25 into 
thermolysin showed docking poses both with the aromatic ring system in the S2
’- and the S1-
subpocket, and we could not rank the poses relative to each other based on scoring. In an X-ray 
complex from the PDB-database (PDB code 1pe5) the inhibitor interacts within the S1’- and 
S2’-subpockets and not in the S1-subpocket, while other X-ray thermolysin complexes with 
small molecular inhibitors also show that the inhibitor may occupy the S1-subsite as well.  In 
the docking poses with the aromatic ring of LM2 in the S1-subpocket, the aromatic ring interacts 
with Phe114, Trp115, Tyr157 and His146. The docking of LM2 and ML25 indicated that both 
orientations could be possible in thermolysin.  As noted previously there are subtle differences 
between the active site of pseudolysin and thermolysin [33].  The S2
’ -subpocket of pseudolysin 
is bigger than that of thermolysin, and the aromatic ring system of LM2 and ML25 seem to 
obtain stable interactions with the S2’ subpocket in pseudolysin and contribute to relative stable 
pseudolysin-inhibitor complexes.   
     Docking into the M4 enzymes showed that amino acids within the S1- and S2’-subpockets 
are important for binding. As discussed in a recent paper, there are structural differences 
between the M4 enzymes and the MMPs in the region of these subpockets [33].   In MMP-2 
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and MMP-9, Leu83 and Tyr142 (MMP-2 numbering in the structure used for docking, the 
fibronectin-domain is replaced by a short peptide linker) are protruding into the binding pocket 
and contribute to a quite narrow access both to the S1’- and S2’-subpockets. These residues 
correspond to Leu188 and Tyr423 (Fig. 3) in the MMP-9 structure. The X-ray complex of a 
hydroxamate inhibitor with MMP-2 (PDB code 1hov) show that the inhibitor is able to tunnel 
in between Leu83 and Tyr142 and interact deeply in a binding pocket that includes Leu83, 
Ala84, Ala136, Leu137, Ala139, Ile141, Thr143, Pro148 and Arg148. These amino acids are 
both from the S1’- and S2’-subpockets. Docking of LM2, the worst MMP-2 and MMP-9 binder, 
but the best M4 binder, indicated that LM2 is not able to interact deeply within the S1’- and S2’-
subpockets of MMP-9 (Fig. 3) and MMP-2, as observed in for the ligand in the 1hov complex 
of MMP-2.  Investigating the top docked poses of ARP101 and EN204  (the inhibitors with 
lowest IC50 values with MMP-2) in MMP-2 showed that they are able to tunnel into the deep 
pocket similarly to that observed in 1hov X-ray structure and are not hindered by Leu83 and 
Tyr142 in MMP-2, and by Leu188 and Tyr423 in MMP-9. They are also able to form most of 
the interactions described above and interact close to the active site Zinc ion as seen in the 1hov 
structure. ARP101 forms hydrogen bonding interactions with Leu83 and Ala84 and with amino 
acids in the S2’-subpocket and the deep S1’-subpocket of MMP-2 and MMP-9. 
     
4. Conclusions 
     Inhibitors targeting bacterial virulence factors such as the M4 zinc metalloproteinases has 
been suggested to be a novel strategy in the development of new antibacterial drugs [34].  
However, zinc metalloproteinase inhibitors of therapeutic value should not interfere with the 
substrate degradation of endogenous zinc metalloproteinases of the infected host. In the present 
study we have synthesised and evaluated a series of hydroxamate derivatives (Fig. 1) as putative 
thermolysin and pseudolysin inhibitors. Some of these compounds (ARP101, EN178, LM2 and 
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FC19) have previously been reported as MMP inhibitors. Knowledge about structural 
determinants giving high affinity for the bacterial M4 zinc metalloproteinases but low affinity 
to human metalloproteinases like the MMPs is important for designing M4 inhibitors of 
therapeutic value in bacterial infections. Low MMP affinity may be important for avoiding the 
serious adverse effects including hepatotoxicity as observed for marimastat and other MMP 
inhibitors. The experimental testing and molecular modelling indicated that the aromatic group 
of the strongest binders (LM2 and ML25) binds to amino acids within the S2
’-subpocket of the 
M4 enzymes. For the other compounds with one aromatic group, the aromatic group is bigger, 
and occupied the S1-subpocket of pseudolysin.  
     In general the compounds bound stronger to pseudolysin than to thermolysin. LM2 which 
binds stronger to thermolysin and pseudolysin than to MMP-2, MMP-9 and ADAM-17 
provides, a good starting point for further hit evolution for a tailored lead design. Compounds 
that not penetrate deeply into a pocket consisting of amino acids within the S1’- and S2’-
subpockets of the MMPs, but bind strongly within the S2’-subpocket of the M4 enzymes may 
increase the affinity for M4 and decrease the affinity for MMP-2 and MMP-9.  
 
5. Experimental section 
5.1 Chemistry  
Melting points were determined on a Kofler hotstage apparatus and are uncorrected. 1H spectra 
were determined with a Varian Gemini 200 MHz spectrometer. Chemical shifts (δ) are reported 
in parts per million downfield from tetramethylsilane and referenced from solvent references. 
Coupling constants J are reported in hertz. The following abbreviations are used: singlet (s), 
doublet (d), triplet (t), double-doublet (dd), broad (br) and multiplet (m). Chromatographic 
separation was performed on silica gel columns by flash column chromatography (Kieselgel 40, 
0.040–0.063 mm; Merck) or using ISOLUTE Flash Si II cartridges (Biotage). The reactions 
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were followed by thin-layer chromatography (TLC) on Merck aluminum silica gel (60 F254) 
sheets that were visualized under a UV lamp and hydroxamic acids were visualized with FeCl3 
aqueous solution. Evaporation was performed in vacuo (rotating evaporator). Sodium sulfate 
was always used as the drying agent. Commercially available chemicals were purchased from 
Sigma-Aldrich. Compounds ARP101, EN178, LM2 and FC19 have been synthesised as 
previously described [21-24]. 
(R)-tert-Butyl 2-(N-isobutylbiphenyl-4-ylsulfonamido)-3-methylbutanoate (2). To a 
solution of sulfonamide 1 (800 mg, 2.0 mmol) in DMF (32 mL) is added 1-iodo-2-methyl 
propane (0.25 mL, 2.2 mmol) followed by potassium carbonate (2.7 g, 20 mmol). The resulting 
mixture was stirred at room temperature for 2 days. The mixture was then diluted with water 
and extracted with EtOAc. The combined organic extracts were washed with brine, dried and 
evaporated under reduced pressure to afford a crude product, which was purified by flash 
chromatography on silica gel (n-hexane/EtOAc 5:1) to give 2 (220 mg, 25% yield) as pure 
yellow oil. 1H-NMR (CDCl3) δ: 0.85 (t, J=6.4 Hz, 6H); 0.93 (d, J=6.6 Hz, 3H); 1.08 (d, J=6.6 
Hz, 3H); 1.27 (s, 9H); 2.02-2.19 (m, 2H); 3.02-3.13 (m, 1H); 3.24-3.34 (m, 1H); 4.05 (d, J=10.6 
Hz, 1H); 7.40-7.52 (m, 3H); 7.56-7.59 (m, 2H); 7.65-7.69 (m, 2H); 7.90-7.94 (m, 2H). 
(R)-2-(N-isobutylbiphenyl-4-ylsulfonamido)-3-methylbutanoic acid (3). TFA (2.1 mL, 27.4 
mmol) was added dropwise to a stirred, ice-chilled solution of tert-butyl ester 2 (217 mg, 0.48 
mmol) in freshly distilled dichloromethane (3.8 mL). The mixture was stirred under these 
reaction conditions for 5h and the solvent was removed in vacuo. Yellow oil, 179 mg, 95% 
yield. 1H-NMR (CDCl3) δ: 0.78 (d, J=6.6 Hz, 3H); 0.85 (d, J=6.6 Hz, 6H); 0.92 (d, J=6.6 Hz, 
3H); 1.93-2.18 (m, 2H); 2.94-3.05 (m, 1H); 3.19-3.30 (m, 1H); 4.03 (d, J=10.8 Hz, 1H); 7.40-
7.53 (m, 3H); 7.58-7.61 (m, 2H); 7.66-7.70 (m, 2H); 7.88-7.92 (m, 2H). 
(R)-N-hydroxy-2-(N-isobutylbiphenyl-4-ylsulfonamido)-3-methylbutanamide (EN204). 1-
[3-(Dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride (EDC) was added portionwise 
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(118 mg, 0.61 mmol) to a stirred and cooled solution (0 ºC) of the carboxylic acid 3 (160 mg, 
0.41 mmol), and O-(tert-butyldimethylsilyl)hydroxylamine (91 mg, 0.61 mmol) in freshly 
distilled CH2Cl2 (20 mL). After stirring at room temperature overnight, the mixture was washed 
with water and the organic phase was dried and evaporated in vacuo. O-silylate intermediate 
was purified by flash chromatography (n-hexane/EtOAc 6:1) to give a yellow oil (68 mg, 32% 
yield). TFA (0.5 mL, 6.5 mmol) was added dropwise to a stirred and ice-chilled solution of O-
silylate (60 mg, 0.11 mmol) in CH2Cl2 (1.0 mL). The solution was stirred under these reaction 
conditions for 5h and the solvent was removed in vacuo. Hydroxamic acid EN204 was obtained 
after trituration with n-hexane and Et2O as a white solid (22 mg, 50% yield). 
1H-NMR (CDCl3) 
δ: 0.36 (d, J=6.6 Hz, 3H); 0.85-0.93 (m, 9H); 2.02-2.34 (m, 2H); 2.93-3.03 (m, 1H); 3.24-3.36 
(m, 1H); 3.63 (d, J=10.9 Hz, 1H); 7.42-7.52 (m, 3H); 7.59-7.63 (m, 2H); 7.71-7.75 (m, 2H); 
7.84-7.88 (m, 2H); 9.42 (br s, 1H). 
3-(Biphenyl-4-ylsulfonamido)propanoic acid (4). Biphenyl-4-sulfonyl chloride (1.56 g, 6.17 
mmol) was added to a solution of 3-aminopropanoic acid (500 mg, 5.61 mmol) in H2O (3.3 mL) 
and dioxane (3.3 mL) containing Et3N (1.17 mL, 8.4 mmol). The mixture was stirred at room 
temperature overnight, the dioxane was evaporated and the residue was treated with EtOAc and 
washed with HCl 1N and brine. Organic layers were then collected, dried over Na2SO4, and 
evaporated in vacuo. The crude product was triturated with n-hexane to yield carboxylate 4 as 
a white solid (1.16 g, 70% yield). Mp: 138-140°C; 1H-NMR [(CD3)2co] δ: 2.57 (t, J=6.7 Hz, 
2H); 3.18-3.27 (m, 2H); 6.60 (t, J=5.4 Hz, 1H); 7.44-7.57 (m, 3H); 7.68-7.78 (m, 2H); 7.87-
8.00 (m, 4H). 
3-(Biphenyl-4-ylsulfonamido)-N-(tert-butyldimethylsilyloxy)propanamide (5). 1-[3-
(Dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride (EDC) was added portionwise 
(188 mg, 0.98 mmol) to a stirred and cooled solution (0 ºC) of the carboxylic acid 4 (200 mg, 
0.65 mmol), and O-(tert-butyldimethylsilyl)hydroxylamine (144 mg, 0.98 mmol) in freshly 
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distilled CH2Cl2 (14 mL). After stirring at room temperature overnight, the mixture was washed 
with water and the organic phase was dried and evaporated in vacuo. O-silylate intermediate 
was purified by flash chromatography (n-hexane/EtOAc 2:1) to give a yellow oil (68 mg, 24% 
yield). 1H-NMR (CDCl3) δ: 0.17 (s, 6H); 0.94 (s, 9H); 2.30-2.45 (m, 2H); 3.22-3.31 (m, 2H); 
5.50 (brs, 1H); 7.40-7.51 (m, 3H); 7.57-7.61 (m, 2H); 7.69-7.73 (m, 2H); 7.90-7.94 (m, 2H). 
3-(Biphenyl-4-ylsulfonamido)-N-hydroxypropanamide (FO9). TFA (0.7 mL, 8.9 mmol) 
was added dropwise to a stirred and ice-chilled solution of O-silylate 5 (68 mg, 0.16 mmol) in 
CH2Cl2 (4.5 mL). The solution was stirred under these reaction conditions for 5h and the solvent 
was removed in vacuo. Hydroxamic acid FO9 was obtained after trituration with Et2O as a 
white solid (25 mg, 50% yield). Mp: 142-144°C; 1H-NMR [(CD3)2CO] δ: 2.34 (t, J=6.4, 2H); 
3.18-3.21 (m, 2H); 6.62 (m, 1H); 7.43-7.56 (m, 3H); 7.72-7.76 (m, 2H); 7.85-7.97 (m, 4H); 
10.02 (s, 1H). 
tert-Butyl 2-(2-(4-hydroxyphenylthio)phenyl)acetate (7). A solution of carboxylic acid 6 (1.3 
g, 5.2 mmol) in toluene (10 mL) containing N,N-dimethylformamide di-tert-butyl acetal (5 mL, 
20.8 mmol) was heated to 95ºC for 3 h. The solvent was then evaporated and the crude product 
was purified by flash chromatography on silica gel (n-hexane/AcOEt = 6:1) to give 7 (1.0 g, 
61 %) as yellow oil. 1H-NMR (CDCl3) δ: 1.47 (s, 9H); 3.66 (s, 2H); 5.27 (s, 1H); 6.74-6.78 (m, 
2H); 7.12-7.27 (m, 6H). 
tert-Butyl 2-(2-(4-(3-(1,3-dioxoisoindolin-2-yl)propoxy)phenylthio)phenyl)acetate (8). A 
mixture of phenol 7 (1.0 g, 3.1 mmol) and K2CO3 (436 mg, 3.2 mmol) in dry acetone (3 mL) 
was stirred for 3 h at room temperature. 2-(3-Bromopropyl)isoindoline-1,3-dione (1.0 g, 3.79 
mmol) in acetone (1 mL) was then added. The mixture was then refluxed for 16 h with constant 
stirring under nitrogen atmosphere, and TLC analysis indicated all the starting materials had 
been consumed. After removal of acetone under reduced pressure, the reaction mixture was 
poured into water and extracted with ethyl acetate. The combined organic layer was washed 
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successively with hydrochloric acid, water, and brine and dried over anhydrous Na2SO4. After 
removal of solvent, the desired product 8 was obtained as a yellow oil (1.6 g, 100 %). 1H-NMR 
(CDCl3) δ: 1.44 (s, 9H); 2.11-2.24 (m, 2H); 3.73 (s, 2H); 3.90 (t, J=6.8 Hz, 2H); 4.01 (t, J=6.0 
Hz, 2H), 6.72-6.76 (m, 2H); 7.10-7.26 (m, 6H); 7.69-7.88 (m, 4H). 
tert-Butyl 2-(2-(4-(3-(1,3-dioxoisoindolin-2-yl)propoxy)phenylsulfonyl)phenyl)acetate (9). 
A solution of Oxone (9.2 g, 15 mmol) in H2O (37 mL) was added slowly to a solution of 8 (950 
mg, 1.88 mmol) in THF/MeOH (3:1, 37 mL). The reaction was stirred at room temperature for 
24 h and the organic solvents were evaporated under reduced pressure. The obtained suspension 
was diluted with H2O and the product was extracted with EtOAc. The combined organic 
extracts were dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure to 
afford 9 as a yellow oil (516 mg, 51% yield). 1H-NMR (CDCl3) δ: 1.39 (s, 9H); 2.15-2.25 (m, 
2H); 3.85-3.91 (m, 4H); 4.04 (t, J=6.0 Hz, 2H); 6.82-6.86 (m, 2H); 7.27-7.31 (m, 1H); 7.37-
7.56 (m, 2H); 7.69-7.87 (m, 6H); 8.03-8.08 (m, 1H). 
2-(2-(4-(3-(1,3-Dioxoisoindolin-2-yl)propoxy)phenylsulfonyl)phenyl)acetic acid (10). TFA 
(4.2 mL, 54.7 mmol) was added dropwise to a stirred and ice-chilled solution of ester 9 (516 
mg, 0.96 mmol) in CH2Cl2 (5 mL). The solution was stirred under these reaction conditions for 
5h and the solvent was removed in vacuo. Carboxylic acid 10 was obtained after trituration with 
Et2O as a white solid (350 mg, 76% yield). Mp: 168-170°C; 
1H-NMR (CDCl3) δ: 2.10-2.21 (m, 
2H); 3.92 (t, J=6,2 Hz, 2H); 4.00-4.06 (m, 4H); 6.74-6.81 (m, 2H); 7.31-7.36 (m, 1H); 7.45-
7.63 (m, 2H); 7.67-7.83 (m, 6H); 8.25-8.30 (m, 1H). 
2-(2-(4-(3-(1,3-Dioxoisoindolin-2-yl)propoxy)phenylsulfonyl)phenyl)-N-
hydroxyacetamide (FC31). 1-[3-(Dimethylamino)propyl]-3-ethyl carbodiimide 
hydrochloride (EDC) was added portionwise (92 mg, 0.47 mmol) to a stirred and cooled 
solution (0 ºC) of the carboxylic acid 10 (153 mg, 0.31 mmol), and O-(tert-
butyldimethylsilyl)hydroxylamine (47 mg, 0.31 mmol) in freshly distilled CH2Cl2 (8 mL). After 
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stirring at room temperature overnight, the mixture was washed with water and the organic 
phase was dried and evaporated in vacuo. O-silylate intermediate was used in the next step 
without further purification (163 mg, 84% yield). 1H-NMR (CDCl3) δ: 0.12 (s, 6H); 0.91 (s, 
9H); 2.17-2.26 (m, 2H); 3.70 (s, 2H); 3.90(t, J=6.4 Hz, 2H); 4.07 (t, J=5.6 Hz, 2H); 6.87-6.91 
(m, 2H); 7.36-7.95 (m, 10H); 9.16 (s, 1H). TFA (1.2 mL, 15.3 mmol) was added dropwise to a 
stirred and ice-chilled solution of O-silylate intermediate (163 mg, 0.27 mmol) in CH2Cl2 (2.1 
mL). The solution was stirred under these reaction conditions for 5h and the solvent was 
removed in vacuo. Hydroxamic acid FC31 was obtained after trituration with Et2O as a white 
solid (121 mg, 91% yield). Mp: 154-155°C; 1H-NMR (CDCl3) δ: 2.13-2.25 (m, 2H); 3.80 (s, 
2H); 3.89 (t, J=6.1 Hz, 2H); 4.07 (t, J=5.9 Hz, 2H); 6.84-6.89 (m, 2H); 7.43-7.53 (m, 3H); 7.69-
7.85 (m, 6H); 7.96-8.00 (m, 1H). 
2-(5-Bromo-N-isopropoxythiophene-2-sulfonamido)acetic acid (12). TFA (3.1 mL, 41 
mmol) was added dropwise to a stirred and ice-chilled solution of ester 11 (300 mg, 0.72 mmol) 
in CH2Cl2 (5.7 mL). The solution was stirred under these reaction conditions for 5h and the 
solvent was removed in vacuo. Carboxylic acid 12 was obtained after trituration with n-hexane 
as a beige solid (213 mg, 83% yield). 1H-NMR (CDCl3) δ: 1.27 (d, J=6.2 Hz, 6H); 3.82 (brs, 
2H); 4.57 (septet, J=6.2 Hz, 1H); 7.17 (d, J=4.0 Hz, 1H); 7.45 (d, J=4.0 Hz, 1H). 
2-(5-Bromo-N-isopropoxythiophene-2-sulfonamido)-N-hydroxyacetamide (ML25). 1-[3-
(Dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride (EDC) was added portionwise 
(172 mg, 0.9 mmol) to a stirred and cooled solution (0 ºC) of the carboxylic acid 12 (213 mg, 
0.6 mmol), and O-(tert-butyldimethylsilyl)hydroxylamine (88 mg, 0.6 mmol) in freshly 
distilled CH2Cl2 (13 mL). After stirring at room temperature overnight, the mixture was washed 
with water and the organic phase was dried and evaporated in vacuo. O-silylate intermediate 
was purified by flash chromatography (n-hexane/EtOAc = 6:1) using a ISOLUTE Flash Si II 
cartridge to give a beige solid (158 mg, 54% yield). 1H-NMR (CDCl3) δ: 0.20 (s, 6H); 0.97 (s, 
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9H); 1.27 (d, J=6.2 Hz, 6H); 3.71 (s, 2H); 4.47 (septet, J=6.2 Hz, 1H); 7.18 (d, J=4.0 Hz, 1H); 
7.46 (d, J=4.0 Hz, 1H); 8.43 (brs, 1H). TFA (1.3 mL, 17.6 mmol) was added dropwise to a 
stirred and ice-chilled solution of O-silylate intermediate (153 mg, 0.31 mmol) in CH2Cl2 (2.5 
mL). The solution was stirred under these reaction conditions for 5h and the solvent was 
removed in vacuo. Hydroxamic acid ML25 was obtained after trituration with Et2O as a white 
solid (87 mg, 74% yield). Mp: 120-121°C; 1H-NMR (CDCl3) δ: 1.26 (d, J=6.2 Hz, 6H); 3.76 
(brs, 2H); 4.47 (septet, J=6.2 Hz, 1H); 7.18 (d, J=4.0 Hz, 1H); 7.46 (d, J=4.0 Hz, 1H); 8.97 (brs, 
1H). 
N-Isopropoxy-4-phenoxybenzamide (13). A solution of 4-phenoxybenzoic acid (500 mg, 
2.33 mmol) and EDC (490 mg, 2.5 mmol) in CH2Cl2 (15 mL) was added to a stirred solution 
of O-isopropyl hydroxylamine hydrochloride (285 mg, 2.5 mmol) and N-methylmorpholine 
(NMM) in freshly distilled CH2Cl2 (15 mL). After stirring at room temperature overnight, the 
mixture was washed with HCl 10%, NaHCO3 solution and brine. The organic phase was dried 
and evaporated in vacuo. The crude product was purified by flash chromatography 
(CH2Cl2/MeOH 20:1) to give a yellow oil (404 mg, 64% yield).
 1H-NMR (CDCl3) δ: 1.30 (d, 
J=6.2 Hz, 6H); 4.26 (septet, J=6.2 Hz, 1H); 6.97-7.06 (m, 4H); 7.13-7.21 (m, 1H); 7.34-7.42 
(m, 2H); 7.69-7.75 (m, 2H); 8.45 (s, 1H). 
(R)-tert-Butyl  4-(1,3-dioxoisoindolin-2-yl)-2-(N-isopropoxy-4-
phenoxybenzamido)butanoate (15). Diisopropyl azodicarboxylate (DIAD) (0.16 mL, 0.82 
mmol) was added dropwise to a solution containing (S)-tert-butyl 4-(1,3-dioxoisoindolin-2-yl)-
2-hydroxybutanoate 14 (100 mg, 0.33 mmol), the amide 13 (90 mg, 0.33 mmol) and 
triphenylphosphine (260 mg, 0.99 mmol) in anhydrous THF (5 mL) under nitrogen atmosphere. 
The resulting solution was stirred for 5h at room temperature and evaporated under reduced 
pressure to afford a crude product which was purified by flash chromatography on silica gel (n-
hexane/EtOAc = 3:1) to yield 15 (85 mg, 45%) as pure yellow oil. 1H-NMR (CDCl3) δ: 1.23-
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1.30 (m, 6H); 1.43 (s, 9H); 2.21-2.32 (m, 2H); 3.95 (t, J=6.7 Hz, 2H); 4.22 (septet, J=6.2 Hz, 
1H); 5.57 (t, J=5.3 Hz, 1H); 6.91-7.15 (m, 5H); 7.30-7.38 (m, 2H); 7.67-7.73 (m, 2H); 7.79-
7.84 (m, 4H). 
(R)-4-(1,3-Dioxoisoindolin-2-yl)-2-(N-isopropoxy-4-phenoxybenzamido)butanoic acid 
(16). TFA (0.61 mL, 7.98 mmol) was added dropwise to a stirred and ice-chilled solution of 
ester 15 (80 mg, 0.14 mmol) in CH2Cl2 (1.5 mL). The solution was stirred under these reaction 
conditions for 5h and the solvent was removed in vacuo. Carboxylic acid 16 was obtained after 
trituration with n-hexane and Et2O as a white solid (66 mg, 94% yield).
 1H-NMR (CDCl3) δ: 
1.24 (d, J=5.6 Hz, 6H); 2.41 (dd, J=6.4 Hz, 2H); 3.94 (t, J=6.7 Hz, 2H); 4.23 (septet, J=5.6 Hz, 
1H); 5.29 (m, 2H); 6.89-6.93 (m, 2H); 7.03-7.07 (m, 2H); 7.16-7.24 (m, 1H); 7.36-7.44 (m, 2H); 
7.65-7.81 (m, 4H); 7.95-7.99 (m, 2H). 
(R)-N-(4-(1,3-Dioxoisoindolin-2-yl)-1-(hydroxyamino)-1-oxobutan-2-yl)-4-
phenoxybenzamide (EN181). 1-[3-(Dimethylamino)propyl]-3-ethyl carbodiimide 
hydrochloride (EDC) (36 mg, 0.19 mmol) was added portionwise to a stirred and cooled 
solution (0 ºC) of the carboxylic acid 16 (66 mg, 0.13 mmol), and O-(tert-
butyldimethylsilyl)hydroxylamine (28 mg, 0.19 mmol) in freshly distilled CH2Cl2 (4 mL). After 
stirring at room temperature overnight, the mixture was washed with water and the organic 
phase was dried and evaporated in vacuo. O-silylate intermediate was purified by flash 
chromatography (n-hexane/EtOAc = 2:1) to give a yellow oil (16 mg). TFA (0.1 mL, 1.37 mmol) 
was added dropwise to a stirred and ice-chilled solution of O-silylate intermediate (15 mg, 0.024 
mmol) in CH2Cl2 (1 mL). The solution was stirred under these reaction conditions for 5h and 
the solvent was removed in vacuo. Hydroxamic acid EN181 was obtained after trituration with 
Et2O as a white solid (8.5 mg, 77% yield).
 1H-NMR (acetone-d6) δ: 2.29-2.41 (m, 2H); 2.86 
(brs, 1H); 3.81-3.95 (m, 2H); 5.25 (dd, J=4.3 Hz, 1H); 6.93-6.98 (m, 2H); 7.10-7.14 (m, 2H); 
7.22-7.29 (m, 1H); 7.44-7.52 (m, 2H); 7.74-7.80 (m, 4H); 7.96-8.01 (m, 2H); 10.33 (s, 1H). 
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N-(1-Adamantyloxy)-4-methoxybenzenesulfonamide (18). A solution of 4-
methoxybenzene-1-sulfonyl chloride (371 mg, 1.79 mmol) in anhydrous THF (5 mL) was 
added dropwise to a stirred and cooled (0 °C) solution of O-(1-adamantyl)oxyamine 17 (300 
mg, 1.79 mmol) and N-methylmorpholine (0.2 mL, 1.79 mmol) in anhydrous THF (5 mL). 
After stirring at room temperature for 4 days, the reaction mixture was diluted with EtOAc and 
washed with H2O. The organic phase was dried over anhydrous Na2SO4, filtered and evaporated 
under reduced pressure. The crude product was purified by flash chromatography on silica gel 
(n-hexane/EtOAc = 4:1) to yield 18 as a white solid (292 mg, 48% yield).1H-NMR (CDCl3) δ: 
1.56 (m, 6H); 1.76 (d, 6H); 2.15 (m, 3H); 3.88 (s, 3H); 6.36 (s, 1H); 6.97-7.01 (m, 2H); 7.82-
7.87 (m, 2H). 
tert-Butyl 2-(N-1-adamantyloxy-4-methoxyphenylsulfonamido)acetate (19). A solution of 
sulfonamide 18 (292 mg, 0.87 mmol) in anhydrous DMF (3 mL) was treated with tert-butyl 
bromoacetate (0.15 mL, 1.02 mmol), caesium carbonate (283 mg, 0.87 mmol) and 
tetrabutylammonium hydrogen sulfate (295 mg, 0.87 mmol). The reaction mixture was stirred 
for 3 days at room temperature, diluted with H2O and extracted with EtOAc. The combined 
organic extracts were dried over anhydrous Na2SO4, filtered and evaporated under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (n-
hexane/EtOAc = 4:1) to yield 19 as a yellow solid (194 mg, 49% yield). 1H-NMR (CDCl3) δ: 
1.49 (s, 9H); 1.62 (m, 6H); 1.90 (d, 6H); 2.18 (m, 3H); 3.75 (s, 2H); 3.88 (s, 3H); 6.98-7.02 (m, 
2H); 7.79-7.83 (m, 2H). 
2-(N-1-adamantyloxy-4-methoxyphenylsulfonamido)acetic acid (20). TFA (1.8 mL) was 
added dropwise to a stirred and ice-chilled solution of ester 19 (194 mg, 0.43 mmol) in CH2Cl2 
(2 mL). The solution was stirred under these reaction conditions for 5h and the solvent was 
removed in vacuo. Carboxylic acid 20 was obtained after trituration with n-hexane and Et2O as 
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a yellow solid (176 mg, 99% yield). Mp: 190-192 °C; 1H-NMR (CDCl3) δ: 1.63 (m, 6H); 1.88 
(d, 6H); 2.2 (m, 3H); 3.80 (d, 2H); 3.89 (s, 3H); 7.01-7.05 (m, 2H); 7.80-7.85 (m, 2H). 
N-hydroxy-2-(N-1-adamantyloxy-4-methoxyphenylsulfonamido)acetamide (CC30). 1-[3-
(Dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride (EDC) (93 mg, 0.48 mmol) was 
added portionwise to a stirred and cooled solution (0 ºC) of the carboxylic acid 20 (176 mg, 
0.48 mmol), and O-(tert-butyldimethylsilyl)hydroxylamine (71 mg, 0.48 mmol) in freshly 
distilled CH2Cl2 (9 mL). After stirring at room temperature overnight, the mixture was washed 
with water and the organic phase was dried and evaporated in vacuo. TFA (1.6 mL) was added 
dropwise to a stirred and ice-chilled solution of O-silylate intermediate (190 mg, 0.36 mmol) in 
CH2Cl2 (3.2 mL). The solution was stirred under these reaction conditions for 5h and the solvent 
was removed in vacuo. Hydroxamic acid CC30 was obtained after trituration with Et2O as a 
white solid (91 mg, 62% yield). 1H-NMR (DMSO-d6) δ: 1.55 (m, 6H); 1.81 (m, 6H); 2.11 (m, 
3H); 3.79 (d, 2H); 3.87 (s, 3H); 7.15-7.20 (m, 2H); 7.76-7.79 (m, 2H); 10.6 (s, 1H). 
 
5.2 Experimental binding studies 
5.2.1 Thermolysin and pseudolysin 
Three times crystallized thermolysin (activity > 7000 units/mg) was from Calbiochem. Some 
pseudolysin was obtained as a gift from Prof. Efrat Kessler, Tel Aviv University Sackler, Israel, 
and in addition obtained from Calbiochem.  DMSO was from Merck. The fluorogenic substrate 
AGLA was obtained from Bachem, while the fluorogenic substrate BLS was from AnaSpec 
(ID: 929-ZN-10).  
     IC50 values of the compounds were measured both for thermolysin and pseudolysin using 
the two fluorogenic substrates, AGLA and BLS. The IC50 values for pseudolysin with the 
AGLA substrate were measured with the use of spectrofluorometer (Perkin Elmer 
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Luminiscence spectrometer LS50B), while the other IC50 values were measured with the 96-
plate readers (Molecular Devices models Gemini XS and Spectra MAX Gemini EM). 
 
5.2.1.1 Instrument and instrument settings. To determine the IC50 value for the potential 
inhibitors, initial rate measurements were performed at 25 °C with the different instruments and 
substrates. The instruments and their settings were as follows: 
    AGLA: These experiments were performed on either a Perkin Elmer LS 50 Luminescence 
spectrometer controlled by the FL WinLab Software Package (Perkin Elmer) or a Spectra Max 
Gemini EM Plate Reader controlled by the computer program Soft Max Pro version 4.3 
(Molecular Devices). All assays were performed with an excitation wavelength of 330 nm and 
an emission wavelength of 460 nm, using slit widths of 10 nm. 
     BLS: Spectra Max Gemini EM Plate Reader controlled by the computer program Soft Max 
Pro version 4.3 (Molecular Devices) or a Spectra Max Gemini XS (03148, Molecular Devices). 
All assays were performed with an excitation wavelength of 328 nm and an emission 
wavelength of 393 nm.  
 
5.2.1.2 Determination of IC50 values using the AGLA substrate. All the potential inhibitors were 
dissolved in 100% DMSO and were further diluted with water to give a concentration of 100 
μM. The enzyme inhibition studies were performed under a set of different conditions which 
varied with substrate and enzyme used as described in the following paragraphs. 
Pseudolysin: The AGLA substrate was dissolved in 50% acetic acid, giving a concentration of 
500 µM. 4 µl of 1.0 µM enzyme was preincubated for 15 minutes at 25 °C with 4 µl of inhibitors 
(appropriate concentrations) and 100 µl of 0.1 M Tris-HCl, 5 mM CaCl2, pH 8.25 and 88 µl 
water (Milli-Q). In the controls, inhibitor was substituted with buffer and in the inhibitor and 
control experiments the final DMSO concentration was less than 5 %. The enzyme reaction was 
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started by adding 4 µl of AGLA to the enzyme-inhibition mixture which resulted in a total 
reaction volume of 200 µl, with final substrate and enzyme concentrations of 10 µM and 20 
nM, respectively, and a pH of 7.8. The initial reaction rate was monitored for 1 minute. Plots 
of vi/v0 against [I] were used to determine the IC50 value where vi and v0 represents the initial 
rate activity in the presence and absence of inhibitor, respectively. The enzyme kinetic program 
in Graph Pad Prism 5 was used to determine the IC50 value, using equation (1): 
vi/v0 = 1/(1+ [ I ] / IC50)     (Eqn. 1) [35] 
All experiments were performed in duplicate. 
     Thermolysin: A stock solution of 2.0 mM AGLA in 100% DMSO was further diluted to 75 
µM in 0.1 M Hepes, pH 7.3, containing 10 mM CaCl2, 0.005% Brij-35. Five µl of enzyme 
solution (4.4 nM) was pre-incubated for 15 minutes at 37 °C with 10 µl of inhibitors 
(appropriate concentrations) and 65 µl of 0.1 M Hepes, 10 mM CaCl2, 0.005% Brij-35, pH 7.3. 
In the controls, the inhibitor was exchanged with buffer. In the inhibitor and control experiments 
the final DMSO concentration was 5 %. The enzyme reaction was started by adding 20 µl of 
AGLA (75 µM) to the enzyme-inhibition mixture which resulted in a total reaction volume of 
100 µl with final substrate and enzyme concentrations of 15 µM and 0.21 nM respectively, and 
a pH of 7.3. The final inhibitor concentrations in the assays varied from 10-3 to 10-10 M. The 
initial rate reaction was followed for 30 minutes at 37 °C. The enzyme kinetic program in 
Sigma-Plot was used to determine the IC50 value and due to the large range of inhibitor 







                             (Eqn. 2) 
 





5.2.1.3. Determination of IC50 values using the BLS substrate. The IC50 values of the 
compounds were measured both for thermolysin and pseudolysin using BLS. Thermolysin; 
assay buffer consisted of 0.1 M Hepes pH 7.5, 10 mM CaCl2 and 0.005 % Brij-35, [substrate] 
= 3.33 μM, [Thermolysin] = 5 nM. Pseudolysin; assay buffer consisted of 0.1 M Hepes pH 7.5, 
10 mM CaCl2, 150 mM NaCl and 0.005 % Brij-35, [substrate] = 1.73 μM, [Pseudolysin] = 5 
nM. The substrate-powder was dissolved in DMSO, and diluted sequential two times in assay 
buffer, so the fixed DMSO contribution with substrate in the assay was 1 % in the thermolysin 
assay and approximately 0.5 % in the Pseudolysin assay. The inhibitors were dissolved in 
DMSO to a stock concentration of 10 mM, and seven inhibitor concentrations were used for 
each inhibitor ranging from low (typical 0.1-1) to high (500) μM. The DMSO contribution was 
at most 5 %, but was often kept below than 1 %. Thermolysin remained unaffected by 6 % 
DMSO in our experiments, and therefore the varied DMSO amounts should not affect the 
outcome. The inhibitors were pre-incubated with enzyme for 1 hour in 96-well microtiter plates 
at room temperature. The enzymatic reaction was started by adding the substrate and the initial 
rate was followed over a period of 15 minutes. Three parallels were performed for control, 
where the inhibitor was replaced with buffer.  The decrease in rate, due to added inhibitor, was 
calculated as percentage (%) relative to the controls (Softmax Pro 4.7.1), and analysed with a 
non-linear curve fitting (Origin 6.0) using equation (1).  
 
5.2.1.4 Kinetic parameters. Prior to determination of the IC50 values, it was necessary to 
determine the Km values for the two enzymes with AGLA and BLS. Each KM determination 
was performed on the Perkin Elmer LS 50 Luminescence spectrometer at 25 °C with AGLA 
and 37 °C with BLS, using the instrument settings described above for respective substrate. 
Initial rates were determined with AGLA concentrations ranging from 30 - 400 µM. All assays 
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were performed in 0.1 M Hepes, 10 mM CaCl2, 0.005 % Brij-35, pH 7.3 with AGLA and pH 
7.5 with BLS, using a final concentration of 2.2 nM thermolysin and 5.0 nM pseudolysin. In 
the case of BLS, initial rates were determined with substrate concentrations ranging from 1.3 
to 10.0 µM, higher substrate concentrations resulted in quenching. For all tests, at least two 
independent experiments were performed to obtain reliable Km values. These were calculated 
from non-linear regression of the Michaelis-Menten equation using the Enzyme kinetic module 
in Sigma Plot.  
 
5.2.2 MMPs and ADAM-17 inhibition assays  
     Recombinant human proMMP-2, proMMP-9 and ADAM-17 (PF133) were purchased from 
Calbiochem.  Proenzymes were activated immediately prior to use with p-
aminophenylmercuric acetate (APMA 2 mM for 1 h at 37 °C for MMP-2, 1 mM for 1 h at 37 °C 
for MMP-9). For assay measurements, the inhibitor stock solutions (10 mM in DMSO) were 
further diluted, at 7 different concentrations (0.01 nM-300 µM) for each MMP in the 
fluorimetric assay buffer (FAB: 50 mM Tris, pH = 7.5, 150 mM NaCl, 10 mM CaCl2 10, 0.05 % 
Brij 35 and 1 % DMSO). Activated enzyme (final concentration 0.5 nM for MMP-2, 1.3 nM 
for MMP-9 and 5 nM for ADAM-17) and inhibitor solutions were incubated in the assay buffer 
for 2 h at 25 °C. ADAM-17 was incubated for 30 min at 37 °C in another buffer at pH = 9 (Tris 
25 mM, ZnCl2 25 µM, Brij-35 0.005%). After the addition of 200 μM of the fluorogenic 
substrate FS-6 (Bachem) in DMSO (final substrate concentration 2 μM), the hydrolysis was 
monitored every 10 sec for 15 min recording the increase in fluorescence (λex = 325 nm, λem = 
395 nm) using a Molecular Devices SpectraMax Gemini XS plate reader. The assays were 
performed in triplicate in a total volume of 200 μL per well in 96-well microtiter plates (Corning, 
black, NBS). The enzyme inhibition activity was expressed in relative fluorescent units (RFU). 
Percent of inhibition was calculated from control reactions without the inhibitor. IC50 was 
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determined using the formula: vi/vo = 1/(1 + [I]/ IC50), where vi is the initial velocity of substrate 
cleavage in the presence of the inhibitor at concentration [I] and vo is the initial velocity in the 
absence of the inhibitor. Results were analysed using SoftMax Pro software (SoftMax Pro 4.7.1 
by Molecular Devices) and GraFit software (GraFit version 4 by Erithecus Software). 
 
5.3 Molecular modelling     
5.3.1 Docking 
     The Internal coordinate mechanics (ICM) program [29] was used for docking the 
compounds into pseudolysin, thermolysin, MMP-2 and MMP-9. The inhibitors were also 
docked into thermolysin using the Glide program of the Schrødinger program package [30]. 
 
5.3.1.1 ICM. Enzyme – inhibitor complexes of pseudolysin (PDB-code: 1u4g), thermolysin 
(PDB-code: 1pe5). MMP-2 (PDB-code: 1hov), and MMP-9 (PDB-code: 1gkc) were obtained 
from the PDB database. The MMP-2 complex used for docking was 1hov. The MMP-2 
structure in the 1hov complex has a short peptide linker replacing the internal fibronectin-
domain, but is still active. This structure has been complexed with hydroxamic acid inhibitor 
(SC-74020) and was therefore used for docking. Crystallographic water molecules and co-
crystallized small molecule inhibitors were removed and hydrogen atoms were added and 
optimized using the ECEPP/3 force field of ICM. The inhibitors were built using ICM and 
minimized before docking. A grid map that included the active site amino acids was calculated, 
and semi-flexible docking with flexible ligands was performed. 
 
5.3.1.2 Glide. The molecules were drawn, hydrogen atoms were added, and the structures were 
energy optimized.  Ligprep was used to generate tautomeric and ionic forms at pH 7.0 +/- 2.0, 
using Ionizer or Epik (including and excluding metal binding states) with default settings. The 
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thermolysin structure was pre-processed with default settings, except that all water molecules 
more than 1 Å from the structure were removed. Het-states was generated (with metal mode), 
and the selected structure was minimized with an RMSD threshold of 0.30 Å relative to the 
starting structure (force field OPLS 2005). The inhibitor molecule was manually deleted before 
a 30 Å grid was generated centroid of the co-crystallised ligand. Ligand docking was conducted 
using both standard precision (SP) and extra precision (EP), with the different multiple ionic 
and tautomeric states produced with Ionizer or epik, respectively.  
 
5.3.2 Molecular dynamics simulation of pseudolysin-ligand interactions  
     The complexes after docking into pseudolysin were used as starting structures for MD 
simulations of pseudolysin-ligand interactions using Amber 9.0. The simulations were 
performed for 24 ns, and the trajectories sampled during 20-24 ns were used for calculation of 
an average pseudolysin-ligand structure using the ptraj package of the AMBER suite of 
programs.  
 
5.3.2.1 Atomic point charges. The electrostatic potentials of each inhibitor were calculated 
using the antechamber program of the AMBER SUITE and the inbuilt AMI-BCC charges were 
used to derive atomic restrained electrostatic point (RESP) charges of the inhibitors [36-39]. 
 
5.3.2.2 Molecular dynamics simulations. A non-bonded approached was used for the metal ions 
[40, 41]. Zinc was assigned a formal charge of +2.0, van der Waal’s radius 0.69Å and well 
depth ε = 0.014 kcal/mol. Calcium was assigned a formal charge of +2.0, van der Waal’s radius 
1.6Å and well depth ε = 0.1 kcal/mol [41]. The coordination of zinc and calcium ions in the 
pseudolysin structure was described by non-bonded energy terms in the calculations [41]. Zinc 
ions were assigned a formal charge of +2.0, van der Waals’ radius 0.69Å and well depth ε = 
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0.014 kcal/mol. Calcium ions were assigned a formal charge of +2.0, van der Waals’ radius 
1.6Å and well depth ε = 0.1 kcal/mol [41].  All minimizations and MD simulations were 
performed with the AMBER 9.0 package [31] and a TIP3P water model.  The AMBER 2003 
force field was used for both ligand bound and free states of pseudolysin. All molecular systems 
(bound and free states) were solvated with a cubic box of water molecules and neutralized by 
counter ions [42]. The Particle Mesh Ewald (PME) method was used for treatment of long range 
electrostatic interactions [43]. The non-bonded cut off radius was 10.0 Å, and the SHAKE 
option [44] was used to constrain bonds involving hydrogen atoms. The dielectric constant was 
1, and all molecular systems were initially minimized by the conjugate gradient method and 
equilibrated for 200 ps of MD. During the equilibration, the temperature was gradually 
increased to 300 K and kept constant post equilibration. The MD simulations were run for a 
total of 24 ns. The time step during MD was 2 fs, and the non-bonded pair list was updated 
every 25 steps.  Due to the +2 charge of the zinc ion and several surrounding anionic residues, 
the zinc atom and its ligated amino acids needed special treatment during MD in order to 
prevent distortion of the active site and the zinc coordination.  Two histidines, a glutamic acid 
and a water molecule coordinate the zinc ion in the active site. Inhibitors usually replace this 
water molecule with a carboxylate, hydroxamate or phosphoramidate group as observed in the 
x-ray structure thermolysin-inhibitor complexes. Harmonic restraining force of 50 kcal/Å and 
distance restraints of 2.1Å-2.5Å was therefore used between the coordinating atoms of the 
hydroxamate and the zinc ion. Further, harmonic restraining force (50 kcal/Å) and a distance 
restraint (2.10Å) were applied between zinc and its amino acid ligands: His 140 (atom NE2); 
His 144 (atom NE2) and Glu 164 (atom OE1). Similar approaches have also previously been 
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Table 1. Inhibition dataa of hydroxamates against thermolysin, pseudolysin (using two different 





MMP-2 MMP-9 ADAM-17 
BLS AGLA BLS AGLA 
ARP101 800 416 798 57 0.0008 [26] 0.0067 [26] 14 
EN178 NT NT NT 103 0.029 [22] 0.0072 [22] 1.1 
EN204 608 243 226 29 0.003 0.0053 NT 
FO9 30 30 79 30 2.4 26 NT 
FC19 146 NT 29 17 0.23 [24] 0.098 [24] 67 
FC31 132 NT 38 7 >10 >10 150 
EN181 NT NT NT 16 9.0 8.2 9.5 
ML25 29 29 31 3.3 1.1 6.2 114 
LM2 9.5 NT 1.9 1.1 34 [23] 81 [23] 100 
CC30 438 90 142 51 2.0 2.0 NT 
a The IC50 values are the average of at least two determinations with a standard deviation of 









Table 2. Amino acids within 4 Å of the ligand in the average complexes from the trajectories 
between 20 and 24 ns of MD. 
Compound Amino acids within 4 Å of the compound 
ARP101 N112, Y114, W115, H140, E141, H144, L153, I154, 
Y155, G160, N163, E164, L197, R198, D221, V222, H223 
FO9 A113, Y114, W115, M120,V137, H140, E141, H144, 
Y155, E164,I190,L197,  V222, H223 
LM2 N112, A113, Y114, W115, H140, H144, Y155, E164, 
L197, R198; D206, S209, H223, H224 
CC30 Y114, W115, D116, H140, E141, H144,Y155, N163, 
E164, V222, H223  
EN178 Y114, W115, D116, G117, H140, E141, H144, Y155, 
E164  
EN204 E111, N112, A113, T114, F129, L132, V137, H140, E141, 
E164, I186, L197, R198, D206, H223, H224  
FC31 N112, Y114, W115, D116, G117, H140, E141, H144, 
Y155, E164, D221, V222, H223 
FC19 N112, A113, Y114, W115, H140, E141, H144, Y155, 
E164, H223 
EN181 N112, A113, Y114, D116, E141, H144, E148, Y155, 
G160, N163, E164, V222, H223.  
ML25 N112, A113, Y114, F129, V137, H140, E141, H144, 






Figure 1. General structure of the hydroxamates used for this study. 
 
Figure 2. ARP101, FO9 and LM2 docked into the active sites of pseudolysin (PLN) and 
thermolysin (TLN). The ligand structure, the most important amino acids for binding and the 
active site zinc are shown. Colour coding of atoms; oxygen: red, nitrogen: blue, grey: carbon 
atoms in PLN and TLN, yellow: carbon atoms in the ligands, cyan: zinc. The directions for the 
subpockets are indicated for the complexes with LM2.  
 
Figure 3.  ARP101, FO9 and LM2 docked into the active sites of MMP-9. The ligand structure, 
the most important amino acids for binding and the active site zinc are shown. Colour coding 
of atoms; oxygen: red, nitrogen: blue, grey: carbon atoms in MMP-9, yellow: carbon atoms in 
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